Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 30;15(7):2069.
doi: 10.3390/cancers15072069.

Retrospective Analysis of a Cohort of Patients with Metastatic Bladder Cancer with Metastatic Sites Limited to the Pelvis and Retroperitoneum Treated at a Single Institution between 2009 and 2020

Alexandre Bertucci  1   2 , Lysian Cartier  3 , Armelle Rollet  1 , Rania Boustany  1 , Werner Hilgers  1
Affiliations

Retrospective Analysis of a Cohort of Patients with Metastatic Bladder Cancer with Metastatic Sites Limited to the Pelvis and Retroperitoneum Treated at a Single Institution between 2009 and 2020

Alexandre Bertucci et al. Cancers (Basel). .

Abstract

Bladder cancer (BC) presenting with pelvic and retroperitoneal lymph nodes presents a therapeutic challenge. The impact of chemoradiotherapy on pelvic and retroperitoneal lymph node metastasis as a consolidation treatment has not been established. Between 2009 and 2020, 502 patients who were treated with first-line chemotherapy for BC in our center, were retrospectively identified. Patients who received chemoradiotherapy or radiotherapy with an equivalent radiation dose superior to 30 Gy were included in the RTCT group, and other patients were included in the control group (CT group). We performed an analysis of progression-free survival (PFS) and overall survival (OS) for these two cohorts using the Kaplan-Meier method. A total of 89 patients were included, 24 in the RTCT group and 65 in the CT group. Chemoradiotherapy improved both OS (p = 0.034) and PFS (p = 0.009) in comparison with chemotherapy alone: 26.3 months (95% IC 0.0-52.9) and 19.4 months (95% IC 5.0-33.7), respectively, in the RTCT group versus 17.2 months (95% IC 13.7-20.6) and 11.2 months (95% IC 8.6-13.8), respectively, in the CT group. Grade 3/4 toxicity was related to chemotherapy and to chemoradiotherapy at levels of 31% and 24%, respectively. For mBC with metastatic regional or retroperitoneal lymph nodes, chemoradiotherapy seems to confer benefits for both OS and PFS.

Keywords: bladder cancer; multidisciplinary approaches; oligometatasis disease; radiochemotherapy; radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow chart. Pts: patients; UC/urothelial cancer; RTCT group: radiotherapy and chemotherapy group; CT group: chemotherapy group.
Figure 2
Figure 2
Overall survival. RT: radiochemotherapy; Chimio: chemotherapy.
Figure 3
Figure 3
Progression-free survival. RT: radiochemotherapy; Chimio: chemotherapy.
See this image and copyright information in PMC

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Antoni S., Ferlay J., Soerjomataram I., Znaor A., Jemal A., Bray F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur. Urol. 2017;71:96–108. doi: 10.1016/j.eururo.2016.06.010. - DOI - PubMed
    1. Pederzoli F., Bandini M., Briganti A., Plimack E.R., Niegisch G., Yu E.Y., Bamias A., Agarwal N., Sridhar S.S., Sternberg C.N., et al. Incremental Utility of Adjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect. Eur. Urol. 2019;76:425–429. doi: 10.1016/j.eururo.2019.06.032. - DOI - PMC - PubMed
    1. von der Maase H., Hansen S.W., Roberts J.T., Dogliotti L., Oliver T., Moore M.J., Bodrogi I., Albers P., Knuth A., Lippert C.M., et al. Gemcitabine and Cisplatin versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study. J. Clin. Oncol. 2000;18:3068–3077. doi: 10.1200/JCO.2000.18.17.3068. - DOI - PubMed
    1. Grivas P.D., Daignault S., Tagawa S.T., Nanus D.M., Stadler W.M., Dreicer R., Kohli M., Petrylak D.P., Vaughn D.J., Bylow K.A., et al. Double-Blind, Randomized, Phase 2 Trial of Maintenance Sunitinib versus Placebo after Response to Chemotherapy in Patients with Advanced Urothelial Carcinoma: Sunitinib in Urothelial Carcinoma. Cancer. 2014;120:692–701. doi: 10.1002/cncr.28477. - DOI - PubMed

LinkOut - more resources